Literature DB >> 30345046

Usefulness of multi-parametric MRI for diagnosis of invasive urothelial cancer: Case reports of bladder and ureteral cancer.

Senji Hoshi1,2, Keiji Horio3, Kenji Numahata2, Kiyotsugu Hoshi1, Vladimir Bilim4, Isoji Sasagawa1.   

Abstract

The presence or absence of metastasis has critical implications for therapeutic decision-making in urothelial cancer (UC). Conventional magnetic resonance imaging (MRI) utilizing anatomic T1- and T2-weighted images has modest efficacy in detecting lymph node and distant metastases in UC. However, incorporation of functional techniques including diffusion weighted imaging and dynamic contrast-enhanced imaging, may improve the accuracy of lesion detection and staging. Multiparametric (mp)MRI is widely used in the imaging of prostate and breast cancers, though its usefulness in UC has yet to be fully elucidated. The present study reports on mpMRI in the context of two cases of bladder and ureteral cancer, and imaging results with pathological diagnosis.

Entities:  

Keywords:  bladder cancer; multi-parametric magnetic resonance imaging; ureter cancer; urothelial cancer

Year:  2018        PMID: 30345046      PMCID: PMC6174391          DOI: 10.3892/mco.2018.1713

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  9 in total

1.  Diagnosis and treatment of pelvic lymph node metastasis in bladder control.

Authors:  S Hoshi; S Orikasa; K I Suzuki; T Takahashi; C Ohyama; K Sato; K Ono
Journal:  Int J Urol       Date:  1999-08       Impact factor: 3.369

2.  Multiparametric 3-T MRI for differentiating low-versus high-grade and category T1 versus T2 bladder urothelial carcinoma.

Authors:  Huan-jun Wang; Margaret H Pui; Yan Guo; Shu-rong Li; Jian Guan; Xiao-ling Zhang; Hua-song Cai
Journal:  AJR Am J Roentgenol       Date:  2015-02       Impact factor: 3.959

3.  An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer.

Authors:  Valeria Panebianco; Ettore De Berardinis; Giovanni Barchetti; Giuseppe Simone; Constantino Leonardo; Marcello Domenico Grompone; Maurizio Del Monte; Davide Carano; Michele Gallucci; James Catto; Carlo Catalano
Journal:  Eur Radiol       Date:  2017-02-08       Impact factor: 5.315

Review 4.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

5.  Interpreting Prostate Multiparametric Magnetic Resonance Imaging: Urologists' Guide Including Prostate Imaging Reporting and Data System.

Authors:  Daniel Christidis; Shannon McGrath; Barry Leaney; Richard O'Sullivan; Nathan Lawrentschuk
Journal:  Urology       Date:  2017-08-18       Impact factor: 2.649

6.  Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection.

Authors:  Huan-jun Wang; Margaret H Pui; Yan Guo; Dong Yang; Bi-tao Pan; Xu-hui Zhou
Journal:  Abdom Imaging       Date:  2014-02

Review 7.  The potential of multiparametric MRI of the breast.

Authors:  Katja Pinker; Thomas H Helbich; Elizabeth A Morris
Journal:  Br J Radiol       Date:  2016-11-02       Impact factor: 3.039

8.  Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.

Authors:  Senji Hoshi; Chikara Ohyama; Kunio Ono; Atsushi Takeda; Shinichi Yamashita; Takashi Yamato; Akihiro Itoh; Makoto Satoh; Seiichi Saito; Yasuhiro Okada; Fumihiko Sohma; Yoichi Arai
Journal:  Int J Clin Oncol       Date:  2004-04       Impact factor: 3.402

9.  PET/CT and MRI in Bladder Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  J Cancer Sci Ther       Date:  2012-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.